Ion-exchange Resins Patents (Class 424/483)
  • Patent number: 8933081
    Abstract: The invention relates to an orodispersible tablet comprising the components pharmaceutically acceptable sildenafil salt (a), polymeric adsorbent (b), in particular cation exchanger resin, sweetener (c), and flavoring (d) and, preferably, mucilage (e) and glidant (f). The invention furthermore relates to a process for the preparation of orodispersible tablets comprising a pharmaceutically acceptable sildenafil salt and to the use of a combination of cation exchanger resin and mucilage for masking the flavor of medicaments for treating erectile dysfunction.
    Type: Grant
    Filed: March 31, 2010
    Date of Patent: January 13, 2015
    Assignee: ratiopharm GmbH
    Inventors: Sven Winter, Max-Werner Scheiwe
  • Patent number: 8808743
    Abstract: Benzonatate resinates of weak acid ion exchange resins having the same distribution of butyl 4-aminobenzoate homologs as exist in the benzonatate listed in the F.D.A. Orange Book as Application No. N011210. These resinates, in simulated gastrointestinal dissolution, release essentially the same distribution of butyl-4 aminobenzoate homologs as exist in the benzonatate listed in the F.D.A. Orange Book as Application No. N011210.
    Type: Grant
    Filed: December 13, 2012
    Date of Patent: August 19, 2014
    Inventors: William Wayne Howard, Russell Francis Somma
  • Patent number: 8623409
    Abstract: An oral clonidine dosage unit providing a twenty-four hour extended release profile following a single dose administration is provided. The dosage unit comprises a pharmaceutically effective amount of a coated complex comprising clonidine bound to a cationic exchange resin, which is characterized by a twenty-four hour release profile with a single peak, wherein said oral clonidine dosage unit provides a therapeutically effective plasma concentration for at least about 70%, or at least 85% of the twenty-four hour period following the single dose administration. Both liquid and solid formulations are provided, as are methods of treating a patient by a single administration of a formulation of the invention so as to achieve a therapeutic effect for 24-hours.
    Type: Grant
    Filed: October 20, 2010
    Date of Patent: January 7, 2014
    Assignee: Tris Pharma Inc.
    Inventors: Ketan Mehta, Yu-Hsing Tu
  • Patent number: 8617602
    Abstract: Multi-layer solid oral dosage immediate release and extended release compositions and methods for delivering drug formulations using weak acid ion exchange resins in abnormally high pH environments.
    Type: Grant
    Filed: April 23, 2012
    Date of Patent: December 31, 2013
    Inventors: William Wayne Howard, Russell Francis Somma, Sajeev Chandran, Pravin Megharji Bhutada, Ashish Ashokkao Deshmukh, Hemant Hanumant Bhalerao
  • Patent number: 8586186
    Abstract: A pressure-sensitive adhesive sheet contains at least a pressure-sensitive adhesive layer containing an acrylic pressure-sensitive adhesive containing an acrylic polymer composition containing an acrylic polymer as a main component and a tackifier containing a tackifying resin as a main component, wherein reflection rate and attached amount in the fogging test in accordance with German Industrial Standard DIN 75201 are 70% or more and 2.0 mg or less, respectively. In the acrylic pressure-sensitive adhesive which forms the pressure-sensitive adhesive layer, a ratio of components having a molecular weight of 300 or less is preferably 4.2% by weight or less based on the total amount of solid matter of the acrylic pressure-sensitive adhesive. Furthermore, in the tackifying resin in the tackifier, a ratio of components having a molecular weight of 300 or less is suitably 4.2% by weight or less based on the total amount of solid matter of the tackifying resin.
    Type: Grant
    Filed: October 26, 2010
    Date of Patent: November 19, 2013
    Assignee: Nitto Denko Corporation
    Inventors: Tomonari Naito, Michio Umeda, Akiko Takahashi
  • Patent number: 8568777
    Abstract: The present invention relates to packaged orally consumable film dosage units for delivery of actives into the oral cavity. In particular, the packaged pharmaceutical product contains a complexate including a complexing agent and an active, an orally consumable film for delivery of the complexate and a package for containing the orally consumable film. The package includes indicia associated therewith. The indicia identifies the complexate as the active ingredient contained in the film, which is as a regulatory approvable chemical entity. The present invention also relates to methods of labeling, pricing, marketing and satisfying governmental regulations for such packaged pharmaceutical products.
    Type: Grant
    Filed: March 30, 2007
    Date of Patent: October 29, 2013
    Assignee: MonoSol Rx, LLC
    Inventor: Richard C. Fuisz
  • Patent number: 8445014
    Abstract: The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides core-shell compositions and pharmaceutical compositions thereof. Methods of use of the core-shell compositions for therapeutic and/or prophylactic benefits are disclosed herein. Examples of these methods include the treatment of phosphate imbalance disorders, hypertension, chronic heart failure, end stage renal disease, liver cirrhosis, chronic renal insufficiency, fluid overload, or sodium overload.
    Type: Grant
    Filed: September 26, 2008
    Date of Patent: May 21, 2013
    Assignee: Relypsa, Inc.
    Inventors: Dominique Charmot, Han-Ting Chang, Eric Connor, Mingjun Liu, Gerrit Klaerner
  • Patent number: 8357398
    Abstract: Oral dosage forms of benzonatate useful for anti-tussive and anti-tussive/combination applications.
    Type: Grant
    Filed: October 20, 2010
    Date of Patent: January 22, 2013
    Assignee: Alitair Pharmaceuticals Inc.
    Inventors: William Wayne Howard, Russell Francis Somma, Doreen Marie Frank
  • Patent number: 8192758
    Abstract: The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides core-shell compositions and pharmaceutical compositions thereof. Methods of use of the core-shell compositions for therapeutic and/or prophylactic benefits are disclosed herein. Examples of these methods include the treatment of phosphate imbalance disorders, hypertension, chronic heart failure, end stage renal disease, liver cirrhosis, chronic renal insufficiency, fluid overload, or sodium overload.
    Type: Grant
    Filed: March 30, 2004
    Date of Patent: June 5, 2012
    Assignee: Relypsa, Inc.
    Inventors: Dominique Charmot, John Fordtran, Han Ting Chang, Eric Connor, Mingjun Liu, Gerrit Klaerner
  • Patent number: 8187617
    Abstract: Immediate release compositions and methods for delivering drug formulations using weak acid ion exchange resins in abnormally high pH environments.
    Type: Grant
    Filed: September 3, 2010
    Date of Patent: May 29, 2012
    Inventors: William Wayne Howard, Russell Francis Somma
  • Patent number: 8119125
    Abstract: Methods and compositions are provided for stabilizing polypeptides for oral administration, particularly where enteric delivery is desirable. By administering the polypeptides with a bile sequestering agent, the stability of the polypeptide can be increased. Pharmaceutical formulations for this purpose are provided.
    Type: Grant
    Filed: October 11, 2006
    Date of Patent: February 21, 2012
    Assignee: Alvine Pharmaceuticals, Inc.
    Inventor: Jonathan David Gass
  • Patent number: 8044017
    Abstract: A method for purifying a polypeptide by ion exchange chromatography is described in which a gradient wash is used to resolve a polypeptide of interest from one or more contaminants.
    Type: Grant
    Filed: September 10, 2003
    Date of Patent: October 25, 2011
    Assignee: Genentech, Inc.
    Inventors: Jefferson C. Emery, Paul J. McDonald, Rhona O'Leary
  • Patent number: 8008378
    Abstract: The present invention provides a taste-masked composition containing an active compound. The composition is taste-masked by employing a loaded polymeric matrix which is produced by incorporating or complexing the active compound on a polymeric matrix having ionic functional groups and removing unbound active compounds from the polymeric matrix.
    Type: Grant
    Filed: July 27, 2004
    Date of Patent: August 30, 2011
    Assignee: Novartis AG
    Inventors: Robert D. Hargens, Yimin Jia, Greg Slominski, Suresh Vayalakkada
  • Patent number: 7488495
    Abstract: The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides compositions comprising potassium binding polymers and pharmaceutical compositions thereof. Methods of use of the polymeric and pharmaceutical compositions for therapeutic and/or prophylactic benefits are disclosed herein. Examples of these methods include the treatment of hyperkalemia, such as hyperkalemia caused by renal failure and/or the use of hyperkalemia causing drugs.
    Type: Grant
    Filed: October 13, 2004
    Date of Patent: February 10, 2009
    Assignee: Relypsa, Inc.
    Inventors: Dominique Charmot, Han Ting Chang, Gerrit Klaerner, Michael James Cope, Mingjun Liu, Futian Liu, Jerry Buysse, Eric Connor, Tony Kwok-Kong Mong, Jun Shao, Deidre Madsen
  • Patent number: 7378109
    Abstract: The present invention discloses compositions, comprising a lipid-polymer matrix to mask the bitter or unpleasant taste of the medicament. The lipid or a blend of lipids, are used in combination with the pH dependent polymer where the said polymer is acid soluble or swellable The process for the preparation of taste masked pharmaceutical compositions of the bitter drugs comprising the said lipid-polymer compositions are disclosed. The concomitant use of the acid soluble polymer, which remains collapsed at the pH of saliva, inhibits the release of drug at that pH and hence they further help in bitterness inhibition. The said compositions deliver substantial amount of the bitter drug immediately at the gastric pH with improved palatability.
    Type: Grant
    Filed: December 23, 2004
    Date of Patent: May 27, 2008
    Assignee: Council of Scientific and Industrial Research
    Inventors: Anupa R. Menjoge, Mohan G. Kulkarni
  • Patent number: 7067116
    Abstract: Physiologically acceptable films, including edible films, are disclosed. The films include a water soluble film-forming polymer, such as pullulan, and a taste masked pharmaceutically active agent, such as dextromethorphan. The taste masking agent is preferably a sulfonated polymer ion exchange resin comprising polystyrene cross-linked with divinylbenzene, such as AMBERLITE. Methods for producing the films are also disclosed.
    Type: Grant
    Filed: March 23, 2000
    Date of Patent: June 27, 2006
    Assignee: Warner-Lambert Company LLC
    Inventors: William S. Bess, Neema Kulkarni, Suhas H. Ambike, Michael P. Ramsay
  • Patent number: 6706285
    Abstract: Disclosed are an enteric coated formulation of a benzimidazole derivative comprising a core and a film of an enteric coating agent on the surface thereof, the core containing a complex of the benzimidazole derivative and an ion-exchange resin, and the enteric coating agent having the degree of substitution by an acidic group of less than 30%, and a method for preparation thereof.
    Type: Grant
    Filed: July 20, 1999
    Date of Patent: March 16, 2004
    Assignee: Hanms Pharm. Co., Ltd.
    Inventor: Jong Soo Woo
  • Patent number: 6685962
    Abstract: Pharmaceutical gastroretentive drug delivery systems for the controlled release of an active agent in the gastrointestinal tract are disclosed, which comprise: (a) a single- or multi-layered matrix comprising a polymer that does not retain in the stomach more than a conventional dosage form selected from (1) degradable polymers that may be hydrophilic polymers not instantly soluble in gastric fluids, enteric polymers substantially insoluble at pH less than 5.5 and/or hydrophobic polymers and mixtures thereof; (2) non-degradable polymers; and any mixtures of (1) and (2); (b) a continuous or non-continuous membrane comprising at least one polymer having a substantial mechanical strength; and (c) a drug; wherein the matrix when affixed or attached to the membrane prevents evacuation from the stomach of the delivery system for a period of time of from about 3 to about 24 hours.
    Type: Grant
    Filed: May 29, 2002
    Date of Patent: February 3, 2004
    Assignee: Yissum Research Development Company Of The Hebrew University Of Jerusalem
    Inventors: Michael Friedman, Eytan Klausner, Eran Lavy, Amnon Hoffman
  • Patent number: 6194000
    Abstract: Disclosed is a method for the therapeutic treatment of pain related to wind up in a human or animal. The method of the invention is practiced by administering to the subject an effective amount of an analgesic pharmaceutical composition which includes a NMDA receptor antagonist in an immediate release form combined with an NMDA receptor antagonist in a sustained release form. The immediate release form and sustained release forn are present in sufficient amounts to diminsh or abolish wind up.
    Type: Grant
    Filed: April 17, 1998
    Date of Patent: February 27, 2001
    Assignee: F.H. Faulding & Co., Limited
    Inventors: Ian Keith Smith, Grant Wayne Heinicke
  • Patent number: 6066336
    Abstract: An improved cholesterol-lowering tablet is manufactured by blending tablet grade cholestyramine with an appropriate amount of lubricant and directly compressing into elongated tablets having a specified thickness. These inner tablets are successfully film coated using aqueous film-coating processes without tablet preheating and by simultaneous spray-drying.
    Type: Grant
    Filed: August 11, 1998
    Date of Patent: May 23, 2000
    Assignee: Bristol-Myers Squibb Company
    Inventors: Ismat Ullah, Gary James Wiley
  • Patent number: 5980882
    Abstract: The invention provides a pharmaceutical composition comprising a drug-resin complex and a chelating agent in which the composition is in the form of a solid or a gel. The invention also provides a method of making such a composition and a method for improving the stability of a pharmaceutical composition.
    Type: Grant
    Filed: April 16, 1997
    Date of Patent: November 9, 1999
    Assignee: Medeva Pharmaceuticals Manufacturing
    Inventor: Martin L. Eichman
  • Patent number: 5935604
    Abstract: The present invention provides a nasal drug delivery composition comprising nicotine or a pharmacologically-acceptable salt or derivative thereof wherein the composition is adapted to delivery a pulse of nicotine for rapid absorption and a controlled release of nicotine for subsequent sustained absorption. The controlled release phase can be achieved by providing an ion-exchange material which will form a complex with the nicotine. The ion-exchange material may be a polymeric material such as a polysaccharide, or may be in the form of bioadhesive ion-exchange microspheres. The pulse release can be achieved by overloading the ion-exchange material with nicotine so that the composition contains some excess nicotine for immediate release and absorption. Alternatively, some nicotine may be associated with a non ion-exchange material which will release the nicotine immediately on contact with the nasal mucosa, for example non-ion-exchange bioadhesive microspheres.
    Type: Grant
    Filed: July 1, 1996
    Date of Patent: August 10, 1999
    Assignee: Danbiosyst UK Limited
    Inventor: Lisbeth Illum
  • Patent number: 5840339
    Abstract: A salt comprising the reaction product of nicotinic acid and an anion exchange resin having a degree of crosslinking with divinylbenzene of less than 4%. These salts are useful in reducing blood cholesterol levels.
    Type: Grant
    Filed: September 3, 1992
    Date of Patent: November 24, 1998
    Inventor: Robert Kunin
  • Patent number: 5837226
    Abstract: A sustained release drug delivery composition and a method of making same are provided which comprises microspheres containing a pharmaceutically active agent, a core of a ion-exchange resin and a polymeric coating completely surrounding the core wherein the coating is water-insoluble and hydrolytically stable in physiological environments. The coating is non-erodible in physiological environments and is characterized by a diffusion constant suitable for the pharmaceutical agent to diffuse from the core to an aqueous environment at a predetermined release rate.
    Type: Grant
    Filed: September 19, 1995
    Date of Patent: November 17, 1998
    Assignee: Vitaphore Corporation C/O Integra Lifesciences Corp.
    Inventors: Lisa B. Jungherr, Thomas B. Ottoboni
  • Patent number: 5718920
    Abstract: A method and particles for binding monovalent cations, each of the particles having a nucleus containing a cation exchange material, and applied thereon, a coating comprising a membrane being permeable for monovalent cations, in particular sodium, potassium, ammonium and hydrogen ions. The membrane is essentially not disintegrated during passage through the intestinal tract of humans or animals and wherein the membrane is more permeable for monovalent cations than for bi- or higher valent cations.
    Type: Grant
    Filed: May 28, 1996
    Date of Patent: February 17, 1998
    Assignee: Salternate B.V.
    Inventor: Annette Notenbomer
  • Patent number: 5688510
    Abstract: A process for producing a pharmaceutical composition is disclosed. In the process, 1 part by weight of a physiologically inert powdery additive, 0.001-1 part by weight of a macromolecular additive per part by weight of said insert powdery additive, and at least one drug substance are used as ingredients and processed en bloc by means of a multi-screw extruder. The drug substance used in the process can be selected from the following group: subliminable drug, volatile drug, drug hydrolyzable in the presence of water, drug which develops whiskers, and hygroscopic or deliquescent drug. The process confers increased physicochemical stability to the pharmaceutical composition and the drug substance contained therein.
    Type: Grant
    Filed: May 17, 1996
    Date of Patent: November 18, 1997
    Assignee: Nippon Shinyaku CO. LTD.
    Inventors: Kouichi Nakamichi, Shougo Izumi, Hiroyuki Yasuura
  • Patent number: 5654004
    Abstract: An oral pharmaceutical preparation releasable in the lower digestive tract, characterized by having a double-coated structure wherein a solid drug having a core containing an active ingredient is covered with both an inner coat made of a cationic polymer and an outer coat made of an anionic polymer.
    Type: Grant
    Filed: May 5, 1995
    Date of Patent: August 5, 1997
    Assignee: Hisamitsu Pharmaceutical Co., Inc.
    Inventors: Minenobu Okayama, Masaru Nakanishi
  • Patent number: 5442008
    Abstract: Stabilized medicinal substances, a process for the preparation thereof, and stable medicinal formulationsStabilized compounds of the formula I ##STR1## in which R, R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 have the stated meanings, and a process for the preparation thereof, are described. The stabilized compounds are suitable for the manufacture of medicinal formulations. The formula I compounds are stabilized by a polymeric protective coating before being compressed in tablet form.
    Type: Grant
    Filed: February 10, 1994
    Date of Patent: August 15, 1995
    Assignee: Hoechst Aktiengesellschaft
    Inventors: Werner Fulberth, Richard Leeb, Manfred Radau, Willi Stammberger
  • Patent number: 5286493
    Abstract: A stabilized solid controlled release dosage form having a coating derived from an aqueous dispersion of an acrylic polymer is obtained by overcoating a substrate including a therapeutically active with an aqueous dispersion of the plasticized acrylic polymer and then curing the coated substrate at a temperature above the glass transition temperature of the plasticized acrylic polymer, until the coated dosage form attains a stabilized dissolution profile substantially unaffected by exposure to storage conditions of elevated temperature and/or elevated relative humidity.
    Type: Grant
    Filed: January 27, 1992
    Date of Patent: February 15, 1994
    Assignee: Euroceltique, S.A.
    Inventors: Benjamin Oshlack, Mark Chasin, Frank Pedi, Jr.
  • Patent number: 5271946
    Abstract: Azelastine-containing pharmaceutical compositions which provide controlled release of the active substance using a sustained release component. The compositions contain azelastine or a physiologically acceptable salt of azelastine, together with 0.001 to 800 parts of sustained release component for each part by weight of azelastine (calculated as base) and the release rate of azelastine is between 0.05 and 5 mg per hour.
    Type: Grant
    Filed: April 10, 1992
    Date of Patent: December 21, 1993
    Assignee: Asta Pharma Aktiengesellschaft
    Inventor: Helmut Hettche
  • Patent number: 5004614
    Abstract: Controlled release devices having a core including an active agent and an outer coating which is substantially impermeable to the entrance of an environmental fluid and substantially impermeable to the release of the active agent during a dispensing period allow the controlled release of the active agent through an orifice in the outer coating.
    Type: Grant
    Filed: August 25, 1989
    Date of Patent: April 2, 1991
    Assignee: Forum Chemicals Ltd.
    Inventor: John N. Staniforth
  • Patent number: 4999189
    Abstract: Stable sustained release wax- and polymer-coated drug-ion exchange resin complexes especially useful in preparing oral suspensions are disclosed.
    Type: Grant
    Filed: November 14, 1988
    Date of Patent: March 12, 1991
    Assignee: Schering Corporation
    Inventors: Patricia W. Kogan, Edward M. Rudnic, Joel A. Sequeira, Imtiaz A. Chaudry
  • Patent number: 4996047
    Abstract: Disclosed are oral pharmaceutical preparations which comprise a pharmacologically active drug bound to small particles of an ion-exchange resin to provide a drug-resin complex having a drug content above a specified value. The drug-resin complex is subsequently coated with a water-permeable diffusion barrier coating that is insoluble in gastrointestinal fluids thereby providing a controllable sustained release of drug under conditions encountered in the gastrointestinal tract.
    Type: Grant
    Filed: November 2, 1988
    Date of Patent: February 26, 1991
    Assignee: Richardson-Vicks, Inc.
    Inventors: William J. Kelleher, Anthony E. Carpanzano
  • Patent number: 4869908
    Abstract: Tablets containing nutritional and therapeutic substances in conjunction with dietrary fibre substances. The tablets can be formulated in two layers which separate the nutritional and therapeutic substances from the fibre.
    Type: Grant
    Filed: January 9, 1987
    Date of Patent: September 26, 1989
    Assignee: K.V. Pharmaceutical Co.
    Inventors: Mitchell I. Kirschner, William H. Dorow
  • Patent number: 4762709
    Abstract: A formulation of a drug wherein the drug is present as a coated, drug-resin complex suspended in a liquid carrier which carrier also contains a second ionic component bearing the same charge as the coated complexed drug, the second ionic component being present as an uncoated, insoluble drug-resin complex.
    Type: Grant
    Filed: January 31, 1986
    Date of Patent: August 9, 1988
    Assignee: Pennwalt Corporation
    Inventor: Jerry L. Sheumaker
  • Patent number: 4663163
    Abstract: A modified polysaccharide material which comprises: (1) polysaccharide covalently bonded to a synthetic polymer; (2) the synthetic polymer being made from (a) a polymerizable compound which is capable of being covalently coupled directly or indirectly to said polysaccharide, and (b) one or more polymerizable compounds containing (i) an ionizable chemcial group, (ii) a chemical group capable of transformation to an ionizable chemical group, (iii) a chemical group capable of causing the covalent coupling of the compound (b) to an affinity ligand or a biologically active molecule or (iv) a hydrophobic compound.
    Type: Grant
    Filed: February 2, 1984
    Date of Patent: May 5, 1987
    Inventors: Kenneth C. Hou, Tung-Ping D. Liao